关键信息
-
基因名
MSLN/Mesothelin
- 应用
-
别名
Pre-pro-megakaryocyte-potentiating factor
-
种属
Mouse
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q61468
-
表达区间
298-600aa
-
分子量
36.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Mesothelin (MSLN) is a cell surface glycoprotein that plays a significant role in cell adhesion, proliferation, and differentiation, and is predominantly expressed in mesothelial cells, with high levels found in various malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer. Its overexpression in tumors makes mesothelin a promising target for cancer immunotherapy and targeted drug delivery systems. Research into recombinant mesothelin proteins aims to better understand its biological functions and interactions, as well as to develop diagnostic and therapeutic applications. By producing recombinant mesothelin, scientists can study its structure, investigate its role in tumorigenesis, and explore its potential in creating cancer vaccines or antibody-drug conjugates. Moreover, recombinant mesothelin can aid in designing targeted therapies by facilitating the development of mesothelin-specific antibodies, which can selectively bind to tumor cells while sparing normal tissues. This specificity is critical in enhancing the efficacy of cancer treatments and minimizing side effects. As a result, ongoing research focuses not only on the characterization and functional analysis of MSLN but also on its translational potential in improving cancer diagnosis and therapy, ultimately aiming to enhance patient outcomes through novel treatment strategies.
